These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
750 related articles for article (PubMed ID: 11195298)
1. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?]. Carnaghi C; Zucali P; Garassino I Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298 [TBL] [Abstract][Full Text] [Related]
2. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574 [TBL] [Abstract][Full Text] [Related]
3. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627 [TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Simpson D; Dunn C; Curran M; Goa KL Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525 [TBL] [Abstract][Full Text] [Related]
5. [New therapeutic options in chemotherapy of advanced colorectal cancer]. Reimer P; Rückle-Lanz H Med Klin (Munich); 2001 Oct; 96(10):593-8. PubMed ID: 11715331 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749 [TBL] [Abstract][Full Text] [Related]
7. Review of the role of CPT-11 in the treatment of colorectal cancer. Rougier P; Mitry E Clin Colorectal Cancer; 2001 Aug; 1(2):87-94. PubMed ID: 12445366 [TBL] [Abstract][Full Text] [Related]
8. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for colorectal cancer. Goyle S; Maraveyas A Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107 [TBL] [Abstract][Full Text] [Related]
10. Current treatments and future perspectives in colorectal and gastric cancer. Wilke HJ; Van Cutsem E Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459 [TBL] [Abstract][Full Text] [Related]
11. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039 [TBL] [Abstract][Full Text] [Related]
12. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G Oncology; 2005; 69(4):283-9. PubMed ID: 16282707 [TBL] [Abstract][Full Text] [Related]
13. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123 [TBL] [Abstract][Full Text] [Related]
15. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502 [TBL] [Abstract][Full Text] [Related]
16. Current status of capecitabine in the treatment of colorectal cancer. Rothenberg ML Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635 [TBL] [Abstract][Full Text] [Related]
17. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419 [TBL] [Abstract][Full Text] [Related]
18. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231 [TBL] [Abstract][Full Text] [Related]
19. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825 [TBL] [Abstract][Full Text] [Related]
20. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. Tsavaris N; Kosmas C; Vadiaka M; Koufos C BMC Cancer; 2002; 2():2. PubMed ID: 11860608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]